Logo for Thor Medical

Thor Medical Investor Relations Material

Latest events

Logo for Thor Medical

Q2 2024

Thor Medical
Logo for Thor Medical

Q2 2024

30 Aug, 2024
Logo for Thor Medical

Q4 2023

28 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Thor Medical

Access all reports
Segment Data
Access more data
Non-current assets by
Geography
Norway
Expenses by
Financials
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutic products for hematological cancers in Norway. The company is developing Betalutin, an antibody radionuclide conjugate, which is in Phase III clinical trial for a range of non-Hodgkin lymphoma indications. It is also developing 177Lu-lilotomab satetraxetan (HH1), a targeted alpha immunotherapy for non-Hodgkin lymphomas. The company has strategic collaboration with NRCF to develop treatment regimens for hematological cancers and other indications using Lutathera or Betalutin; and with Servier S.A.S., as well as Cytodyn Inc.